A Phase 1/2 study of evofosfamide, zalifrelimab, and balstilimab in advanced cancers
Recruiting Phase 1,Phase 2 NCT06782555
Study Description
A Study of Investigational Drugs Evofosfamide, Zalifrelimab, and Balstilimab in Treating Advanced Prostate, Pancreatic, and Head and Neck Cancers
Study Details
- Registry ID:
- NCT06782555
- Conditions:
- Metastatic Prostate Cancer, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Pancreatic Cancer
- Phase:
- Phase 1,Phase 2
- Target Enrollment:
- 71 participants
- Start Date:
- Age Range:
- 18–999 years
- Healthy Volunteers:
- No
Study Locations (1 site)
-
MD Anderson Cancer Center
Houston, Texas, United States
Interested in Participating?
Check your eligibility and learn more about this study on TrialScreen.